JBC Advanced Peptides, Inc.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M002497200 on June 5, 2000

J. Biol. Chem., Vol. 275, Issue 33, 25322-25329, August 18, 2000
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
275/33/25322    most recent
M002497200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Valentine, J. E.
Right arrow Articles by Parker, M. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Valentine, J. E.
Right arrow Articles by Parker, M. G.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Mutations in the Estrogen Receptor Ligand Binding Domain Discriminate between Hormone-dependent Transactivation and Transrepression*

Janet E. ValentineDagger, Eric Kalkhoven§, Roger White, Sue Hoare, and Malcolm G. Parker

From the Molecular Endocrinology Laboratory, Imperial Cancer Research Fund, 44 Lincoln's Inn Fields, London WC2A 3PX, United Kingdom

Received for publication, March 24, 2000, and in revised form, May 31, 2000

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The estrogen receptor (ER) suppresses transcriptional activity of the RelA subunit of nuclear factor-kappa B in a hormone-dependent manner by a mechanism involving both the receptor DNA binding domain and ligand binding domain (LBD). In this study we examine the role of the ER LBD in mediating ligand-dependent RelA transrepression. Both ERalpha and ERbeta inhibit RelA in response to 17beta -estradiol but not in the presence of antihormones. We have identified residues within the ERalpha LBD that are responsible for receptor dimerization and show that dimerization is necessary for transactivation and transrepression. Moreover we have generated mutant receptors that have lost their ability to inhibit RelA but retain their capacity to stimulate transcription and conversely mutants that are transcriptionally defective but capable of antagonizing RelA. Overexpression of p160 and cAMP-response element-binding protein-binding protein/p300 co-activators failed to relieve repression of RelA, which is consistent with the demonstration that RelA inhibition can occur independently of these co-activators. These findings suggest it is unlikely that sequestration of these cofactors required for ER transcriptional activation can account for hormone-dependent antagonism of RelA. The identification of ER mutants that discriminate between transactivation and transrepression implies that distinct surfaces within the LBD are involved in mediating these two receptor functions.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The pleiotropic effects of estrogens are mediated by estrogen receptors (ERs),1 which function as hormone-activated transcription factors regulating the expression of a variety of estrogen-responsive genes. In common with other members of the nuclear receptor (NR) superfamily, ER contains three functional domains, an N-terminal region with a hormone-independent activation function (AF1), a conserved central DNA binding domain (DBD), and a C-terminal ligand binding domain (LBD), which is responsible for high affinity ligand binding, dimerization, and hormone-dependent activation (AF2) (1-3). There are two forms of ER, ERalpha , and ERbeta , which share a high degree of homology in their DBD and LBD but contain divergent N-terminal domains (4, 5). In response to hormone binding, ER homodimers contact estrogen response elements (ERE) located within the regulatory sequences of target genes, resulting in the recruitment of co-activator proteins and consequent initiation of gene transcription (6, 7). Elucidation of the crystal structure of ERalpha and ERbeta LBD has revealed that they share a common modular structure with the LBD of related NRs, which can be divided into 12 discrete helices (see Refs. 8-11, and the references therein). Comparison of these unliganded and liganded crystal structures suggests that upon ligand binding the LBD undergoes a conformational change whereby the C-terminal helix (H12 in ER) is realigned over the ligand binding pocket and in ER is packed against H3, H5/6, and H11 (8-11). The activity of ERalpha AF2 is dependent on the integrity of a hydrophobic interaction surface generated by conserved amino acids in H3, H4/5, and H12 (12-14).

In addition to stimulating transcription by directly binding cognate response elements within the promoters of responsive genes, NRs are able to regulate gene expression in the absence of DNA binding by modulating the activity of other transcription factors. A well documented example of cross-talk between transcription factors is the mutual antagonism between AP1 and NRs including glucocorticoid receptor (GR) (15-17), retinoic acid receptor, and retinoic X receptor (18-20) and thyroid hormone receptor (21). Functional synergism has been documented between ER and AP1 (22) and ER and SP1 (23), and inhibition of GATA-1 by ER is reported to contribute to the suppressive effect of estrogen on erythroid differentiation (24). Estrogen plays an essential role in bone homeostasis by down-regulating interleukin-6 production in osteoblasts and marrow stromal cells (25). Analysis of the interleukin-6 proximal promoter revealed that the estrogen-dependent reduction in interleukin-6 transcriptional activity occurred in the absence of ER DNA binding (26, 27) and was mediated through interleukin-6 transcriptional activators NF-kappa B and to a lesser extent CCAAT enhancer-binding protein (27, 28).

NF-kappa B is a key inducible regulator of multiple genes involved in proliferation and immune functions. In its latent state, NF-kappa B is sequestered in the cytoplasm through association with inhibitory Ikappa B proteins. Activation of a variety of signaling pathways leads to the phosphorylation and degradation of Ikappa B, resulting in the release of NF-kappa B and subsequent translocation to the nucleus where it binds to DNA recognition elements and stimulates gene transcription (29, 30). Proteins comprising the NF-kappa B family share a conserved N-terminal Rel homology domain, which contains the DNA binding domain, dimerization interface, and nuclear localization signals that are masked when this region interacts with Ikappa B. Transcriptionally active NF-kappa B is composed of homo- or heterodimers of various family members, most typically heterodimers of RelA (p65), which contains two C-terminal transcription activation domains, and NF-kappa B1 (p50) (29, 30). In addition to ER-mediated repression of NF-kappa B (27, 28), hormone-dependent inhibition of RelA transcriptional activity has been described for GR (31-33), progesterone receptor (34), androgen receptor (AR) (35), and the mineralocortocoid receptor (36). In common with AP1/NR cross-talk, NF-kappa B and hormone receptors are mutually antagonistic as RelA is able to reciprocally inhibit receptor activity (27, 28, 33-35). However, in contrast to AP1, RelA transrepression is restricted to the steroid hormone receptor subgroup of NRs, with thyroid hormone receptor and retinoic acid receptor exhibiting no demonstrable effect on RelA transactivation (32).

A number of models have been proposed to account for the mechanism of steroid hormone receptor-mediated NF-kappa B transrepression including (a) up-regulation of Ikappa B expression resulting in sequestration of NF-kappa B in the cytoplasm (33, 37), (b) formation of a receptor·NF-kappa B complex leading either to inhibition of NF-kappa B DNA binding (33, 38, 39) or to transcriptional interference of DNA-bound NF-kappa B (28, 32, 34), or (c) competition for a limiting common transcriptional mediator (40-42). Functional studies in transiently transfected cells using receptor deletion mutants have indicated that both the DBD and LBD are required for ligand-dependent inhibition of RelA (28, 29, 32, 34, 38). In particular the integrity of key conserved amino acids within the C-terminal zinc finger of steroid hormone receptor DBDs is essential for GR transrepression of RelA (36). In this study we have examined the role of specific residues within the ERalpha LBD in mediating ligand-dependent inhibition of RelA activity. Based on the recently determined structural models of NR LBDs, we have identified residues that are essential for receptor dimerization and demonstrate that dimerization is required for both receptor transcriptional activity and antagonism. Using point mutagenesis of the LBD we have identified transcriptionally inactive ERalpha mutants that retain their ability to suppress RelA and conversely mutants that activate transcription but have lost their capacity to inhibit RelA. Discrimination between the transactivation and transrepression properties of the receptor suggests that different surfaces in the LBD are involved in mediating these two ligand-dependent functions and moreover that the p160/CBP cofactors required for ER-induced gene transcription are unlikely to be involved in functional antagonism of NF-kappa B.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Plasmids-- The following wild-type and mutant mouse estrogen receptors have been described previously: pMT2 MOR, (ERalpha ) G525R, L543A/L544A (43), pMT2 and pSP65 K366A (13), pMT2 and pSP65 Y541A (44), pSP64 MOR, L543A/L544A, M547A/L548A, D542N/E546Q/D549N, Delta 540-552 (12), GST-SRC1 () (45), and pSG5 ERalpha (14). The F371A MOR mutant was generated by recombinant polymerase chain reaction and subcloned into pSP65 and pMT2. The pMT2 M547A/L548A, D542N/E546Q/D549N, and Delta 540-552 plasmids were made by transferring receptors as EcoRI fragments from pSP64 into pMT2; and the pMT2 ERbeta plasmid was subcloned as a blunt-ended BamHI fragment from pSP65 into pMT2 (46). The plasmids PDMLacZ, RelA cDNA pBluescript SK+, and the ICAM-tk-Luc reporter containing three NF-kappa B sites from the ICAM-1 promoter were a kind gift of Bart van der Burg and have been previously described (47, 48). RelA cDNA was digested from RelA pBluescript as a HindIII-XbaI fragment that was end-filled and ligated into the SmaI site in pSG5. The pSG5 TIF2, pCMVbeta -p300, pRc/Rous sarcoma virus CBP, and 2XERE-pS2-CAT reporter plasmids were kind gifts of Dr. P. Chambon, Dr. R. Goodman, and Dr. B. Katzenellenbogen. The 2XERE-pS2-pGL3 reporter was made by subcloning the 2XERE-pS2 promoter region as an Asp718 and NcoI fragment from 2XERE-pS2-CAT into the pGL3 vector. Recombinant polymerase chain reaction using overlapping oligonucleotides containing base substitutions was used to generate the ERalpha helix 11 mutants pSG5 L508A/L512A/L515A, L508E/L512E/L515E, A509E, S516A/R519A, H520A/N523A, and S516A/R519A/H520A/N523A using wild-type pSG5 ERalpha template and to make the RelA mutant pSG5-RelA L453A/L454A. All polymerase chain reaction-derived mutant constructs were verified by automated sequencing.

Transient Transfection Experiments-- HeLa and COS-1 cells were maintained in Dulbecco's modified Eagle's medium with 10% fetal bovine serum (Life Technologies, Inc.). For transient transfection assays, cells were plated into 24-well plates in phenol red-free Dulbecco's modified Eagle's medium containing 5% dextran-charcoal-stripped fetal calf serum. Cells were transfected using a modified calcium phosphate co-precipitation method (49) with either 1 µg of ICAM-tk-Luc reporter plasmid, 150 ng of PDMLacZ internal control plasmid, 10 ng of pSG5-RelA, and 250 ng of estrogen receptor expression plasmids or with 1 µg of either 2XERE-pS2-CAT or 2XERE-pS2-pGL3 reporter, 150 ng of PDMLacZ, and 10 ng of estrogen receptor expression plasmids. Where appropriate, empty expression vectors were added to equalize the amount of DNA present in each well, and where indicated 100 ng of co-activators SRC1, TIF2, CBP, and p300 were cotransfected with reporter and expression plasmids. After 16 h the cells were washed, fresh medium containing ethanol vehicle, 10-8 M 17beta -estradiol (E2), 10-7 M 4-hydroxytamoxifen (OHT), or 10-7 M ICI 182,780 (ICI) was added as shown, and the cells were incubated for a further 24 h. Subsequently cells were washed in phosphate-buffered saline and harvested in lysis buffer (10 mM Tris-HCl, pH 8.0, 1 mM EDTA, 150 mM NaCl, 0.65% Nonidet P-40), and the extracts were assayed for luciferase (12) and CAT (50) activities. Reporter activities were then standardized against beta -galactosidase activity of the internal control vector PDMLacZ measured by the Galacto-Light chemiluminescent assay (Tropix). For Western analysis, wild-type and mutant receptors were overexpressed in COS-1 cells, whole cell extracts were prepared, and protein content was determined as described previously (13).

Gel Retardation Assay-- In vitrotranslated ERalpha wild-type and mutant receptors were synthesized using the TNT-coupled in vitro translation system (Promega). Proteins were incubated with a 32P-labeled double-stranded oligonucleotide probe containing a consensus ERE from the vitellogenin A2 gene promoter in the presence of preimmune serum or ERalpha -specific MP16 antibody as described previously (51). Receptor-DNA complexes were resolved from unbound DNA on nondenaturing 7% polyacrylamide gels and were visualized by autoradiography.

Western Blotting-- Whole cell extracts were prepared from COS-1 cells transfected with wild-type or mutant ERalpha expression vectors. Samples containing 5 µg of total protein were separated by SDS-polyacrylamide gel electrophoresis and transferred onto nitrocellulose membranes by electroblotting. The membranes were blocked in phosphate-buffered saline containing 3% nonfat milk powder, washed in phosphate-buffered saline with 0.05% Tween 20, and incubated for 1 h with either the MP16 polyclonal antibody raised against the 130-142 region of mouse ERalpha (51) or the H222 monoclonal antibody raised in rat against human ERalpha . Following washing, the membranes were incubated for 30 min with horseradish peroxidase-coupled anti-rabbit or anti-rat immunoglobulins (DAKO), respectively, the membranes were washed, and bound antibodies were visualized with the ECL western detection system (Amersham Pharmacia Biotech).

GST Pull-down Assays-- GST and GST-SRC1-(570-780) fusion proteins were expressed in bacteria and bound to glutathione-Sepharose 4B beads (Amersham Pharmacia Biotech) using the method previously described (52). Proteins were synthesized in vitro from wild-type and mutant ERalpha cDNA templates using the TNT-coupled in vitro translation system (Promega) in the presence of [35S]methionine. The 35S-labeled proteins were incubated with GST or GST-SRC1 fusion proteins coupled to beads for a minimum of 3 h in NETN buffer (100 mM NaCl, 1 mM EDTA, 20 mM Tris-HCl, pH 8.0, 0.5% Nonidet P-40) containing protease inhibitors in the presence or absence of 10-6 M E2. Samples were washed in NETN, and bound proteins were separated by SDS-polyacrylamide gel electrophoresis. Gels were stained with Coomassie Blue to confirm equivalent amounts of GST proteins were present followed by detection of labeled proteins by fluorography.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Estrogen Receptor-mediated Transrepression of RelA Is Abolished by Antihormones-- The ability of ER to modulate RelA activity in the presence of various ligands was determined in HeLa cells cotransfected with a RelA expression plasmid and ICAM-tk-Luc reporter containing three NF-kappa B-response elements in the presence or absence of ERs. Cells were subsequently treated with either no hormone (NH), E2, OHT, or ICI, and the effect on RelA transactivation is presented in Fig. 1. Consistent with previous findings, expression of ERalpha in the presence of E2 resulted in a 5-fold decrease in RelA activity. The receptor also inhibited RelA activity in the absence of ligand, a phenomenon that has been previously noted with ER, progesterone receptor, and AR (28, 34, 35). To address whether this effect could be attributed to residual steroids present in the medium, we made use of the ERalpha mutant G525R, which cannot bind E2 but retains responsiveness to OHT (53). Cotransfection of RelA and G525R resulted in a hormone-independent decrease in RelA activity relative to RelA alone, although this reduction was less than with wild-type ERalpha in the absence of hormone. As expected, the addition of E2 had no further effect on G525R-mediated RelA transrepression. This finding suggests that low levels of estrogens in the culture medium may, in part, account for the observed ligand-independent inhibition; however, the unoccupied receptor is capable of functionally interfering with RelA transcriptional activity. We next examined the effect of hormone on the modulation of RelA activity by ERbeta (Fig. 1). In common with ERalpha , expression of ERbeta resulted in a decrease in RelA activity, which was further reduced in the presence of E2.


View larger version (42K):
[in this window]
[in a new window]
  		Fig. 1.   ER-mediated transrepression of RelA is inhibited by antihormones. HeLa cells were transiently transfected with the ICAM-tk-Luc reporter and RelA expression plasmid together with wild-type ERalpha , G525R mutant, and ERbeta . Control cells (C) were transfected with reporter and empty expression plasmids. Following transfection, cells were washed and treated for 24 h with ethanol vehicle (NH), 10-8 M E2, 10-7 M OHT, or 10-7 M ICI. Cell extracts were prepared and analyzed for luciferase and beta -galactosidase activities. Normalized values are expressed relative to RelA activity in the absence of ligand (100%) and represent the mean ± S.E. of at least three independent experiments assayed in duplicate.

Antihormones abrogate the ability of the ER to stimulate transcription of ERE-containing reporter genes in many cell types. It was therefore of interest to determine whether these agents also antagonize the inhibitory effect of ER on RelA transcription. Treatment with OHT and ICI had no effect on RelA activity alone but completely relieved transrepression of RelA mediated by ERalpha and ERbeta (Fig. 1). In addition, exposure to OHT abolished the inhibitory effect of the G525R mutant on RelA. The above findings demonstrate that both ERalpha and ERbeta mediate similar ligand-dependent actions on RelA transcriptional activity.

Dimerization Is Necessary for Both the Transactivating and Transrepressing Functions of the ER-- We have previously characterized a region within ERalpha , which is responsible for receptor dimerization (51). Subsequent elucidation of the crystal structure of the E2-bound LBD of ERalpha enabled us to identify candidate residues within the helix 11 dimerization domain that may be directly involved in forming contacts between ERalpha monomers (8, 9). The surface of this domain can be divided into two regions comprising a group of hydrophobic residues at the top of helix 11 (Leu508, Leu512, Leu515) surrounding Ala509 and a cluster of mainly charged residues toward the C terminus of helix 11 (Ser516, Arg519, His520, Asn523). To investigate the role of these two regions in dimer formation and their consequent effect on ER transcriptional activation and functional antagonism of RelA, we replaced each of the amino acids with alanine. The hydrophobic leucines were additionally altered to glutamic acid residues (L508E/L512E/L515E), and Ala509 was replaced with a charged glutamic acid residue (A509E).

All mutant receptors bound ligand with high affinity (data not shown). The DNA binding capacity of in vitro translated wild-type and mutant receptors to a 32P-labeled ERE was determined by gel shift assay in the presence or absence of E2 and MP16, an antibody specific for ERalpha . This antibody is capable of restoring dimerization and DNA binding to dimerization defective mutant receptors (Fig. 2A) (51). Substitutions L508A/L512A/L515A and A509E at the N terminus of helix 11 reduced the DNA binding activity of the mutant receptors, whereas replacement of the leucines with glutamic acid residues, L508E/L512E/L515E, completely abolished the capacity of the receptor to bind to an ERE (left panel). The addition of MP16, however, restored the DNA binding capability of all three mutant receptors indicating that their DNA binding domains were intact. Mutations to the C-terminal end of helix 11 were less deleterious to DNA binding as mutants S516A/R519A, H520A/N523A, and S516A/R519A/H520A/N523A bound DNA in the presence and absence of hormone and were supershifted by MP16 to a comparable extent as wild-type ERalpha (right panel). We conclude that N-terminal Leu508/Leu512/Leu515 and Ala509 residues in the dimer interface identified by the ERalpha crystal structure (8, 9) are crucial for dimerization so that their replacement results in reduced DNA binding activity.


View larger version (53K):
[in this window]
[in a new window]
  		Fig. 2.   Transactivation and transrepression require ERalpha dimerization. A, ERalpha dimers are necessary for DNA binding. In vitro translated wild-type and mutant receptors were analyzed for DNA binding activity in a gel shift assay using a 32P-labeled ERE in the presence or absence of E2 and an ERalpha -specific antibody MP16. Protein·DNA complexes were separated on 7% native polyacrylamide gels and detected by autoradiography. B, mutations that disrupt dimerization impair ER-mediated transcription and RelA inhibition. HeLa cells were transiently transfected with (left panel) a 2XERE-pS2-pGL3 luciferase reporter together with wild-type ERalpha , mutant receptors, or empty pSG5 expression vector or (right panel) the ICAM-tk-Luc reporter and RelA in combination with wild-type ERalpha , mutant receptors, or empty pSG5 expression vector. Control cells (C) were transfected with the relevant reporter and empty expression vectors. Cells were exposed to 10-8 M E2 or vehicle (NH) for 24 h prior to harvesting. The reporter gene activities were assayed, and results were expressed as ER activity from a 2XERE-pS2-pGL3 normalized for transfection efficiency using a beta -galactosidase internal control (left panel) and for ICAM-tk-Luc transfections (right panel) relative to beta -galactosidase standardized RelA activity in the absence of ligand (100%). Results shown represent the mean ± S.E. of at least three independent experiments assayed in duplicate. C, Western blot analysis of ERalpha wild-type and mutant receptors overexpressed in COS-1 cells and detected with the ERalpha -specific polyclonal antibody MP16.

We next compared the ability of the mutant receptors to activate transcription from an ERE reporter gene and to modulate RelA transcriptional activity (Fig. 2B). HeLa cells were transiently transfected with wild-type ERalpha or mutant receptors together with a 2XERE-pS2-Luc reporter gene, and the resulting normalized ER transcriptional activity in the presence and absence of E2 is illustrated in the left panel. HeLa cells were then transiently transfected with the RelA expression plasmid, and the wild-type ERalpha or mutant receptors in the presence and absence of E2 and the effect on NF-kappa B-mediated transactivation relative to RelA alone (100%) are shown in the right panel. Western blot analysis demonstrated that the various receptors were expressed at equivalent levels (Fig. 2C).

As anticipated ERalpha -activated transcription of the ERE reporter gene in a ligand-dependent manner (Fig. 2B, left panel) and caused an ~5-fold reduction in RelA activity in response to hormone (Fig. 2B, right panel). In line with their impaired DNA binding capacities, receptors L508A/L512A/L515A and A509E exhibited attenuated ER transcriptional activity, yet retained their ability to antagonize RelA in an E2-dependent fashion (right panel). In contrast substitution of leucines Leu508/Leu512/Leu515 with glutamic acid residues rendered the dimerization defective mutant receptor both transcriptionally inactive (left panel) and incapable of down-regulating RelA in the presence of hormone (right panel, compare NH and E2 bars). The other mutant receptors, S516A/R519A, H520A/N523A, and S516A/R519A/H520A/N523A, were able to both stimulate ERE transcription (left panel) and to inhibit RelA activity in the presence of E2 (right panel). These findings imply that dimerization is necessary not only for efficient ERalpha -mediated transcriptional activation but also for ligand-dependent RelA transrepression.

Transcriptionally Deleterious Mutations within the ER LBD Have Divergent Effects on Transrepression-- Previous studies using receptor deletion mutants have demonstrated that the DBD and LBD both play a role in down-modulation of RelA by steroid hormone receptors (27, 28, 32, 34). To examine the contribution of discrete residues required for ligand-dependent transactivation within the LBD to hormone-dependent RelA transrepression, we used full-length receptors with point mutations in the LBD, which retain their capacity to bind DNA and ligand. The mutant receptors selected for this study contain alterations of residues within helicies 3, 4, and 12. In the presence of ligand these residues form part of a surface for co-activator interactions and are therefore required for receptor transcriptional activation (12-14). These mutants have been described elsewhere (see "Experimental Procedures") with the exception of F371A, where the phenylalanine residue at position 371 in helix 4 was replaced by alanine.2 Western blot analysis with an ERalpha -specific antibody H222 revealed that the receptors were expressed at similar levels (Fig. 3A). The ability of the wild-type ERalpha and various LBD mutants to stimulate transcription of a 2XERE-pS2-CAT reporter and to regulate RelA-mediated transactivation in transiently transfected HeLa cells in the presence and absence of E2 is shown in Fig. 3B.


View larger version (32K):
[in this window]
[in a new window]
  		Fig. 3.   ERalpha LBD mutants differ in their ability to mediate ligand-dependent transcription and transrepression. A, Western blot analysis of ERalpha wild-type and mutant receptors overexpressed in COS-1 cells and detected with an estrogen receptor-specific monoclonal antibody H222. B, HeLa cells were transiently transfected with (left panel) the 2XERE-pS2-CAT reporter together with wild-type ERalpha , mutant receptors, or empty pMT2 expression vector or (right panel) the ICAM-tk-Luc reporter and RelA in combination with wild-type ERalpha , mutant receptors, or empty pMT2 expression vector. Control cells (C) were transfected with the relevant reporter and empty expression vectors. Cells were exposed to 10-8 M E2 or vehicle (NH) for 24 h prior to harvesting. The reporter gene activities were assayed and normalized for transfection efficiency using a beta -galactosidase internal control. Results from ICAM-tk-Luc transfections (right panel) are expressed relative to RelA activity in the absence of ligand (100%) and represent the mean ± S.E. of at least three independent experiments assayed in duplicate. The left panel shows a representative experimental result of comparative receptor activities on a 2XERE-pS2-CAT reporter (see text for previous references).

In the presence of E2, ERalpha stimulated transcription from the 2XERE-pS2-CAT reporter by ~25-fold (Fig. 3B, left panel) and reduced RelA activity by about 90% (right panel). Interestingly, substitution of the tyrosine residue at position 541 with alanine, which resulted in a constitutively active receptor ((44), left panel), did not lead to ligand-independent inhibition of RelA, but rather to a hormone-responsive phenotype similar to wild-type ERalpha (right panel). The remaining mutations had a deleterious effect on receptor transcriptional activity (left panel). The transcriptionally defective helix 12 mutants Delta 540-552 and L543A/L544A ((12), left panel) demonstrated virtually no ligand-dependent suppression of RelA ((12), right panel) implying that residues within helix 12 are required for both these receptor functions. The helix 4 mutant F371A and the helix 12 mutant D542N/E546Q/D549N were capable of stimulating transcription from the reporter gene, albeit at approximately half the magnitude of ERalpha ((12), left panel), but they completely lost the ability to inhibit RelA in a hormone-dependent manner (right panel, compare F371A and D542N/E546Q/D549N NH and E2 bars). In contrast the helix 3 mutant K366A and the helix 12 mutant M547A/L548A exhibited significantly impaired transcriptional activation ((12, 13), left panel) but retained their capacity for hormone-dependent transrepression (right panel, compare NH versus E2 for each mutant).

The mutants can therefore be divided into several categories, receptors that have impaired ability to transactivate but can inhibit RelA in a ligand-dependent manner (K366A and to a lesser extent M547A/L548A), receptors that are capable of stimulating transcription but have lost their capacity for ligand-dependent transrepression (F371A and D542N/E546Q/D549N), a constitutively active receptor that exhibits hormone-dependent repression (Y541A), and receptors that are unable to mediate ligand-dependent transcription or transrepression (Delta 540-552 and L543A/L544A). Together these data demonstrate the importance of the integrity of individual residues within the LBD in conferring ER/RelA antagonism and moreover enable discrimination between the transactivation and transrepression properties of the receptor.

Ligand-dependent Repression of RelA Is Independent of ER Co-activator Binding-- A potential mechanism underlying functional interference between ER and RelA may be competition for limiting concentrations of common cofactors. Candidates include the cAMP-response element-binding protein-binding protein CBP/p300 family, which are essential co-activators of both NF-kappa B and NR-mediated transcription and p160 family members including SRC1 and TIF2 that are additionally required for nuclear receptor transcriptional activity and have been proposed to play a role in NF-kappa B-dependent gene expression (42, 54-59). To address this hypothesis we overexpressed these co-activators in HeLa cells transiently transfected with RelA and an NF-kappa B-responsive ICAM-tk-Luc reporter gene in the presence or absence of ERalpha (Fig. 4A). Under similar experimental conditions in HeLa cells where p160 family members SRC1 and TIF2 potentiated ERalpha -stimulated transcription of an ERE reporter by at least 3-fold (data not shown), overexpression of SRC1, TIF2, p300, and CBP had no effect on RelA alone. As anticipated, cotransfection of ERalpha caused a decrease in RelA activity that was further down-regulated in the presence of E2. Addition of the co-activators as illustrated in Fig. 4A and in titration experiments (data not shown) failed to relieve ER-mediated ligand-dependent RelA transrepression.


View larger version (38K):
[in this window]
[in a new window]
  		Fig. 4.   Functional antagonism of RelA does not correlate with mutant receptor/co-activator interactions. A, overexpression of co-activators fails to rescue ER-mediated RelA repression. HeLa cells were cotransfected with the ICAM-tk-Luc reporter and RelA and with co-activators SRC1, TIF2, p300, or CBP either in the presence or absence of ERalpha . Control cells (C) were transfected with the ICAM-tk-Luc reporter and empty expression vectors. Cells were treated without (NH) or with 10-8 M E2 for 24 h prior to harvesting. Results are expressed as described in Fig. 1. B, ERalpha LBD mutants differ in their ability to interact with SRC1. In vitro translated [35S]methionine-labeled wild-type and mutant receptors were incubated with GST or GST-SRC1-(570-780) protein fusions in the absence (-) or presence of 10-6 M E2. Bound complexes were separated by SDS-polyacrylamide gel electrophoresis, and labeled proteins were visualized by fluorography. 1/10 input represents 10% of the total amount of 35S-labeled receptor used in each reaction. C, ERalpha dimerization defective mutants are able to associate with SRC1. GST pull-down assay with in vitro translated [35S]methionine-labeled wild-type and helix 11 mutant receptors incubated with GST or GST-SRC1-(570-780) protein fusions in the absence (-) or presence of 10-6 M E2 as described above.

We next sought to determine whether there was a correlation between the ability of the ERalpha mutants to interact with co-activators and their capacity to inhibit RelA activity. 35S-labeled in vitro translated wild-type and mutant receptors were incubated with GST alone and GST fused to the region of SRC1 previously shown to bind the LBD of ERalpha (45). As demonstrated in Fig. 4B, the ERalpha LBD receptor mutants described in Fig. 3 differed in their ability to interact with SRC1 in the presence of E2. Wild-type ERalpha and the Y541A receptor variant bound SRC1 (Fig. 4B) and inhibited RelA activity in response to treatment with E2 (Fig. 3B, right panel). Conversely F371A, L543/544A, and Delta 540-552 failed to interact with GST-SRC1 (Fig. 4B) and were unable to repress RelA in a ligand-dependent manner (Fig. 3B, right panel). Binding of SRC1 to K366A and M547A/L548A was significantly impaired (Fig. 4B), whereas these mutants were capable of down-regulating RelA activity in the presence of hormone (Fig. 3B, right panel). Furthermore the D542N/E546Q/D549N mutant was capable of weakly associating with SRC1 (Fig. 4B) yet had lost the ability to mediate ligand-dependent RelA transrepression (Fig. 3B, right panel). These results indicate that inhibition of RelA transcriptional activity by the ER can be dissociated from interaction with p160 co-activators.

We have previously identified specific residues of the ERalpha LBD helices 3, 5, and 12, which are critical in forming an interface for p160 co-activator interactions (13, 14, 45). The amino acids in helix 11 described in Fig. 2, which differed in their capacities to mediate transactivation and transrepression, do not form part of this co-activator binding surface. To further investigate the role of co-activators in ER/RelA cross-talk we examined the relationship between association of these helix 11 mutant receptors with SRC1 and the ability to inhibit RelA in response to E2. As illustrated in Fig. 4C, all in vitro translated mutants were able to bind GST-SRC1 in the presence of E2. Transrepression studies with these mutants (Fig. 2B, right panel) demonstrated that the dimerization defective mutant L508E/L512E/L515E was incapable of suppressing RelA in a hormone-dependent manner, suggesting that binding to SRC1 is not sufficient to allow inhibition of RelA by ERalpha . These data support the above finding that the ability to functionally interfere with RelA transcriptional activity can be independent of association with co-activators and furthermore is consistent with the inability to relieve RelA transrepression under conditions where co-activator concentrations are not limiting. Taken together, these results suggest that sequestration of p160 or CBP/p300 co-activators is unlikely to be the principle cause of ER-mediated antagonism of RelA transcriptional activity.

ER-mediated Transrepression of RelA Is Independent of the RelA LXXLL Motif-- Recently we and others have identified an alpha -helical leucine motif, LXXLL (where L is leucine and X is any amino acid), present in NR co-activator proteins that is both necessary and sufficient for interaction with NR (60-62). Substitution of the leucine doublet with a pair of alanines in motifs within co-activators abolished their interaction with NRs (61). The Rel homology domain at the N terminus of RelA has been shown to directly interact with GR in vitro and in addition the C-terminal transactivation domain is necessary for cross-talk with steroid hormone receptors (47). The presence of a leucine motif at position 450-454 in the C-terminal transactivation domain of RelA led us to investigate whether interference with RelA transactivation may be mediated by direct RelA/ER contact via this sequence. The pair of leucines within the RelA LXXLL motif was replaced with alanines, and the ability of ERalpha to repress the mutated RelA was assessed in transiently transfected HeLa cells. Although the motif is located within a leucine-rich region of the transactivation domain, which is important for RelA transactivation (47, 63), mutation of this sequence did not have any effect on RelA transcriptional activity (Fig. 5). Cotransfection with ERalpha repressed the activity of the mutated RelA to a similar extent to wild-type RelA, indicating that this motif is not necessary for conferring transcriptional repression by the ER.


View larger version (30K):
[in this window]
[in a new window]
  		Fig. 5.   The integrity of the RelA LXXLL motif is not necessary for ER-mediated transrepression. Wild-type and mutated RelA (RelA mt) in which the leucines at positions 453 and 454 were substituted with alanines were transiently transfected into HeLa cells with the ICAM-tk-Luc reporter both with and without ERalpha , in the absence (NH) and presence of 10-8 M E2. Control cells (C) were transfected with reporter and empty expression plasmids. Results are presented as described in Fig. 1.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Steroid hormones have been shown to inhibit the transcriptional activity of NF-kappa B by a mechanism that involves both the DBD and LBD of their cognate receptors (28, 29, 32, 34, 38). Several reports have characterized features of the receptor DBD that are necessary to confer antagonism (36, 64, 65), but little is know about the role of specific regions within the LBD. In our study of transrepression of NF-kappa B by the ER we have examined the contribution of residues implicated in dimerization and required for ligand-dependent transcription mediated by AF2. Because the crystal structure of ERalpha indicates that the dimer interface is comprised primarily of residues in helix 11 (8, 9), we generated specific mutations in the N- and C-terminal portions of this helix. We found that replacement of hydrophobic amino acids toward the N terminus of helix 11, Leu508/Leu512/Leu515, with alanine or glutamic acid residues impaired or abolished, respectively, the DNA binding and ligand-dependent transcriptional activity of the receptor. We conclude that reduced DNA binding activity is caused by impaired receptor dimerization. This is supported by our observation that DNA binding activity could be restored in vitro by addition of the antibody MP16, which we have previously demonstrated can restore DNA binding of dimerization defective mutant receptors (51). The substitutions, which do not affect the integrity of the DBD, do not appear to alter the overall structure of the LBD as these mutants retain their ligand binding affinity and the ability to interact with SRC1 (Fig. 4C). Moreover, given that the mutations are predicted to be on the dimer interface of the LBD, they are unlikely to affect other functions. Therefore in agreement with the prediction from the crystal structure of the receptor (8, 9), we conclude that residues in the N-terminal portion of helix 11 are essential for ERalpha dimerization and high affinity DNA binding.

The inability of the L508E/L512E/L515E mutant to inhibit RelA activity suggests that receptor dimerization is essential not only for transcriptional activation but also for transrepression. The observation that L508A/L512A/L515A and A509E retain the capacity to antagonize RelA suggests that the extent to which these mutants were able to form dimers was sufficient to mediate transrepression. This finding is consistent with the comparative level of the DNA binding and transactivation activities of these mutants (Fig. 2, A and B) and the amount of wild-type receptor necessary to suppress RelA being greater than that required for transactivation.3 Our finding that receptor dimerization is necessary for both the transactivating and transrepressing functions of ERalpha seems to differ from the requirements of other steroid hormone receptors (36, 64-67). However in contrast to our mutants, GR dimerization and AR DBD mutants were generated by introducing substitutions into the DBD thereby reducing association between the monomers on DNA. Thus the LBDs of these mutant receptors remain intact. Our data indicate that dimerization via residues in the N terminus of helix 11 in the ERalpha LBD is required for both transcriptional activation and transrepression properties of the ERalpha receptor.

Ligand-dependent transcription by ERalpha mediated by AF2 has been shown to depend on residues in helices 3, 4/5, and 12 (12-14). In this study we demonstrate that specific residues within these helicies are essential not only for transactivation but also for hormone-dependent inhibition of RelA (Fig. 3B). Moreover the correct alignment of helix 12 is important for both processes, because transrepression by ERalpha and ERbeta occurs in the presence of estrogen but not tamoxifen, which results in its misalignment (Fig. 1) (8-10). However we have generated ERalpha LBD mutants, which enable discrimination between the stimulatory and inhibitory properties of the receptor. We have found that some of the residues that are necessary for transactivation (Lys366, Met547, and Leu548) are not required for transrepression, and conversely certain residues that are required for ligand-dependent inhibition of RelA (Phe371, Asp542, Glu546, Asp549) are less critical for ER transcriptional activity, whereas others are essential for both functions (Leu543, Leu544). These findings indicate that the two properties of the receptor are mediated by both common and distinct surfaces on the LBD. Furthermore we have demonstrated that certain LBD mutants (K366A and M547A/L548A), which exhibit impaired transcriptional activity (Fig. 3B) and were unable to interact with SRC1 (Fig. 4B), retained their ability to inhibit RelA (Fig. 3B). Conversely the dimerization defective mutant L508E/L512E/L515E, which was able to bind SRC1 (Fig. 4C), had lost the capacity to repress RelA (Fig. 2B). These observations suggest that the recruitment of p160/CBP families of co-activators is not essential to mediate ERalpha transrepression, which is consistent with the observation that overexpression of these co-activators failed to relieve the inhibitory effects of ERalpha on RelA transcriptional activity (Fig. 4A). Taken together our data indicate that competition and sequestration of the p160/CBP co-activators cannot account for the estrogen-dependent transrepression of RelA.

In agreement with our findings, overexpression of SRC1 has also been reported to have no effect on modulating ER-dependent down-regulation of NF-kappa B in either HeLa or HEK-293 cells (68). Similar conclusions were drawn for AP1 transrepression by the thyroid hormone receptor, because the integrity of AF2 in the thyroid hormone receptor did not alter the ability of the receptor to inhibit AP1 (69). However other studies have demonstrated that overexpression of CBP in transiently transfected cells does rescue hormone-dependent down-regulation of AP1 by retinoic acid receptor and GR (54) and overcomes reciprocal GR/RelA (42), AR/RelA, and AR/AP1 cross-talk (41). Thus the importance of co-activators in mediating functional antagonism seems to vary depending on the receptor and target transcription factor. Our results indicate that estrogens inhibit NF-kappa B transcription by a mechanism that does not depend on the integrity of ERalpha AF2 and its ability to interact with p160 co-activators.

We and others have demonstrated that alpha -helical LXXLL motifs present within certain co-activators are sufficient to mediate direct protein-protein contacts with the LBDs of nuclear receptors (60-62). The C-terminal transactivation domain of RelA contains a consensus LXXLL motif, which is located in a region that is required for efficient transactivation (47, 63), for the reciprocal suppression of GR activation (47), and within a domain that is necessary for the recruitment of CBP/p300 (70). Based on these data, it was conceivable that RelA contributed to the E2-dependent inhibitory effects of the receptor by interacting either directly or indirectly with ERalpha via this motif. However, substitution of the leucines with alanines did not alter down-regulation of RelA activity by the ERalpha , indicating that the RelA LXXLL motif is not involved in ER ligand-dependent transrepression (Fig. 5). Increasing evidence suggests the mechanism of transrepression of NF-kappa B in vivo may involve a combination of factors, the importance of which may vary between different cell types and steroid hormone receptors. For instance, up-regulation of Ikappa B expression appears to contribute to progesterone receptor antagonism of NF-kappa B in T47D cells (64, 71) and to GR-mediated inhibition of NF-kappa B activity in HeLa cells (33), T-lymphocytes (37), and pulmonary epithelial A549 cells (71) but not in fibroblast (72) or endothelial cells (72, 73) and does not play a role in ER- or AR-mediated NF-kappa B transrepression (28, 64).

In conclusion we have shown a requirement for ERalpha dimerization and identified specific residues within the ERalpha LBD, which are required for ligand-dependent inhibition of RelA. Furthermore we have described ERalpha LBD mutations that discriminate between the stimulatory and inhibitory functions of the receptor and demonstrated that RelA transrepression can occur independently of interaction with co-activators. It is possible that RelA may bind cofactors that also associate with the ER in a ligand-dependent manner; however, our data suggest that it is unlikely that sequestration of co-activators that are required for ER activation can account for hormone-dependent antagonism of NF-kappa B. Estrogen receptor-dependent repression of NF-kappa B-induced genes is important in maintaining bone density (25, 26) and in mediating the protective effects of estrogen in the cardiovascular system (74). The demonstration that hormone-dependent transactivation and transrepression by the ER are separable functions enables future identification of therapeutic agents, which selectively modulate these processes.

    ACKNOWLEDGEMENTS

We thank S. Wissink and B. van der Burg for providing reagents and helpful discussion of this work, I. Goldsmith for oligonucleotides, G. Clark and A. Davies for automated DNA sequencing, C. Nolan (Abbott Laboratories) for monoclonal antibody H222, and A. Wakeling (Zeneca Pharmaceuticals) for 4-hydroxytamoxifen and ICI 182,780. We are extremely grateful to members of the Molecular Endocrinology Laboratory for their helpful discussions and comments on the manuscript.

    FOOTNOTES

* This research was supported by grants from the International Association for Cancer Research (to J. E. V.) and the Netherlands Organization for Scientific Research (NWO) (to E. K.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger Present address: Breakthrough Toby Robins Breast Cancer Centre, Institute of Cancer Research, 237 Fulham Rd., London SW3 6JB, UK.

§ Present address: Laboratory for Molecular Carcinogenesis, Leiden University Medical Centre, Wassenaarseweg 72, 2333 AL Leiden, The Netherlands.

To whom correspondence should be addressed. Tel.: 44 207 269 3280; Fax: 44 207 269 3094; E-mail: M.Parker@icrf.icnet.uk.

Published, JBC Papers in Press, June 5, 2000, DOI 10.1074/jbc.M002497200

2 P. Henttu and M. Parker, unpublished results.

3 J. E. Valentine and M. G. Parker, unpublished data.

    ABBREVIATIONS

The abbreviations used are: ER, estrogen receptor; NR, nuclear receptor; AF, activation function; DBD, DNA binding domain; LBD, ligand binding domain; ERE, estrogen response element; GR, glucocorticoid receptor; NF-kappa B, nuclear factor kappa B; Ikappa B, inhibitor kappa B; AR, androgen receptor; GST, glutathione S-transferase; ICAM, intracellular adhesion molecule-1; CAT, chloramphenicol acetyltransferase; Luc, luciferase; E2, 17beta -estradiol; OHT, 4-hydroxytamoxifen; ICI, ICI 182,780; NH, no hormone; CBP, cAMP-response element-binding protein-binding protein; SRC, steroid receptor co-activator; TIF, transcriptional intermediary factor.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Parker, M. G. (1993) Curr. Opin. Cell Biol. 5, 499-504
2. Beato, M., Herrlich, P., and Schütz, G. (1995) Cell 83, 851-857
3. Mangelsdorf, D. J., Thummel, C., Beato, M., Herrlich, P., Schültz, G., Umesono, K., Blumberg, B., Kastner, P., Mark, M., Chambon, P., and Evans, R. M. (1995) Cell 83, 835-839
4. Kuiper, G. G., Enmark, E., Pelto-Huikko, M., Nilsson, S., and Gustafasson, J.-Å. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 5925-5930
5. Mosselman, S., Polman, J., and Dijkema, R. (1996) FEBS Lett. 392, 49-53
6. Bevan, C., and Parker, M. (1999) Exp. Cell Res. 253, 349-356
7. Glass, C. K., and Rosenfeld, M. G. (2000) Genes Dev. 14, 121-141
8. Brzozowski, A. M., Pike, A. C. W., Dauter, Z., Hubbard, R. E., Bonn, T., Engström, O., Öhman, L., Greene, G. L., Gustafsson, J.-Å., and Carlquist, M. (1997) Nature 389, 753-788
9. Shiau, A. K., Barstad, D., Loria, P. M., Cheng, L., Kushner, P. J., Agard, D. A., and Greene, G. L. (1998) Cell 95, 927-937
10. Pike, A. C. W., Brzozowski, A. M., Hubbard, R. E., Bonn, T., Thorsell, A.-G., Engstrom, O., Ljunggren, J., Gustafsson, J.-A., and Carlquist, M. (1999) EMBO J. 18, 4608-4618
11. Wurtz, J.-M., Bourguet, W., Renaud, J.-P., Vivat, V., Chambon, P., Moras, D., and Gronemyer, H. (1996) Nat. Struct. Biol. 3, 87-94
12. Danielian, P. S., White, R., Lees, J. A., and Parker, M. G. (1992) EMBO J. 11, 1025-1033
13. Henttu, P. M. A., Kalkhoven, E., and Parker, M. G. (1997) Mol. Cell. Biol. 17, 1832-1839
14. Mak, H. Y., Hoare, S., Henttu, P. M. A., and Parker, M. G. (1999) Mol. Cell. Biol. 19, 3895-3909
15. Jonat, C., Rahmsdorf, H. J., Park, K. K., Cato, A. C. B., Gebel, S., Ponta, H., and Herrlich, P. (1990) Cell 62, 1189-1204
16. Schule, R., Rangarajan, P., Kliewer, S., Ransone, L. J., Bolado, J., Yang, N., Verma, I. M., and Evans, R. M. (1990) Cell 62, 1217-1226
17. Yang-Yen, H. F., Chambard, J. C., Sun, Y. L., Smeal, T., Schmidt, T. J., Drouin, J., and Karin, M. (1990) Cell 62, 1205-1215
18. Nicholson, R. C., Mader, S., Nagpal, S., Leid, M., Rochette-Egly, C., and Chambon, P. (1990) EMBO J. 9, 4443-4454
19. Schule, R., Rangarajan, P., Yang, N., Kliewer, S., Ransone, L. J., Bolado, J., Verma, I. M., and Evans, R. M. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 6092-6096
20. Salbert, G., Fanjul, A., Piedrafita, F. J., Lu, X. P., Kim, S. J., Tran, P., and Pfahl, M. (1993) Mol. Endocrinol. 7, 1347-1356
21. Zhang, X. K., Wills, K. N., Husmann, M., Hermann, T., and Pfaul, M. (1991) Mol. Cell. Biol. 11, 6016-6025
22. Webb, P., Lopez, G. N., Uht, R. M., and Kushner, P. J. (1995) Mol. Endocrinol. 9, 443-456
23. Porter, W., Saville, B., Hoivik, D., and Safe, S. (1997) Mol. Endocrinol. 11, 1569-1580
24. Blobel, G. A., Sieff, C. A., and Orkin, S. H. (1995) Mol. Cell. Biol. 15, 3147-3153
25. Jilka, R. L., Hangoc, G., Girasole, G., Passeri, G., Williams, D. C., Abrams, J. S., Boyce, B., Broxmeyer, H., and Manolagas, S. C. (1992) Science 257, 88-91
26. Pottratz, S. T., Bellido, T., Mocharia, H., Crabb, D., and Manolagas, S. C. (1994) J. Clin. Invest. 93, 944-950
27. Ray, A., Prefontaine, K. E., and Ray, P. (1994) J. Biol. Chem. 269, 12940-12946
28. Stein, B., and Yang, M. X. (1995) Mol. Cell. Biol. 15, 4971-4979
29. Baldwin, A. S. (1996) Annu. Rev. Immunol. 14, 649-681
30. Verma, I. M., Stevenson, J. K., Schwartz, E. M., Van Antwerp, D., and Miyamoto, S. (1995) Genes Dev. 9, 2723-2735
31. Ray, A., and Prefontaine, K. E. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 752-756
32. Caldenhoven, E., Liden, J., Wissink, S., van de Stolpe, A., Raaijmakers, J., Koenderman, L., Okret, S., Gustafasson, J.-Å., and van der Saag, P. T. (1995) Mol. Endocrinol. 9, 401-412
33. Scheinman, R. I., Gualberto, A., Jewell, C. M., Cidlowski, J. A., and Baldwin, A. S. (1995) Mol. Cell. Biol. 15, 943-953
34. Kalkhoven, E., Wissink, S., van der Saag, P. T., and van der Berg, B. (1996) J. Biol. Chem. 271, 6217-6224
35. Palvimo, J. J., Reinikainen, P., Ikonen, T., Kallio, P. J., Moilanen, A., and Jänne, O. A. (1996) J. Biol. Chem. 271, 24151-24156
36. Liden, J., Delaunay, F., Rafter, I., Gustafsson, J.-Å., and Okret, S. (1997) J. Biol. Chem. 272, 21467-21472
37. Auphan, N., DiDonato, J. A., Rosette, C., Helmberg, A., and Karin, M. (1995) Science 270, 286-290
38. Ray, P., Ghosh, S. K., Zhang, D.-H., and Ray, A. (1997) FEBS Lett. 409, 79-85
39. Galien, R., and Garcia, T. (1997) Nucleic Acids Res. 25, 2424-2429
40. McKay, L. I., and Cidlowski, J. A. (1998) Mol. Endocrinol. 12, 45-56
41. Aarnisalo, P., Palvimo, J. J., and Jänne, O. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 2122-2127
42. Sheppard, K.-A., Phelps, K. M., Williams, A. J., Thanos, D., Glass, C. K., Rosenfeld, M. G., Gerritsen, M. E., and Collins, T. (1998) J. Biol. Chem. 273, 29291-29294
43. Lahooti, H., White, R., Danielian, P. S., and Parker, M. G. (1994) Mol. Endocrinol. 8, 182-188
44. White, R., Sjöberg, M., Kalkhoven, E., and Parker, M. G. (1997) EMBO J. 16, 1427-1435
45. Kalkhoven, E., Valentine, J. E., Heery, D. M., and Parker, M. G. (1998) EMBO J. 17, 232-243
46. Cowley, S. M., Hoare, S., Mosselman, S., and Parker, M. G. (1997) J. Biol. Chem. 272, 19858-19862
47. Wissink, S., van Heerde, E. C., Schmitz, M. L., Kalkhoven, E., van der Burg, B., Baeuerle, P. A., and van der Saag, P. T. (1997) J. Biol. Chem. 272, 22278-22284
48. van de Stolpe, A., Caldenhoven, E., Stade, B. G., Koenderman, L., Raaijmakers, J. A. M., Johnson, J. P., and van der Saag, P. T. (1994) J. Biol. Chem. 269, 6185-6192
49. Chen, C., and Okayama, H. (1987) Mol. Cell. Biol. 7, 2745-2752
50. Sleigh, M. J. (1986) Anal. Biochem. 156, 251-256
51. Fawell, S. E., Lees, J. A., White, R., and Parker, M. G. (1990) Cell 60, 953-962
52. Cavaillès, V., Dauvois, S., Danielian, P. S., and Parker, M. G. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 10009-10013
53. Danielian, P. S., White, R., Hoare, S. A., Fawell, S. E., and Parker, M. G. (1993) Mol. Endocrinol. 7, 232-240
54. Kamei, Y., Xu, L., Heinzel, T., Torchia, J., Kurokawa, R., Gloss, B., Lin, S.-C., Heyman, R. A., Rose, D. W., Glass, C. K., and Rosenfeld, M. G. (1996) Cell 85, 403-414
55. Gerritsen, M. E., Williams, A. J., Neish, A. S., Moore, S., Shi, Y., and Collins, T. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 2927-2932
56. Perkins, N. D., Felzien, L. K., Betts, J. C., Leung, K., Beach, D. H., and Nabel, G. J. (1997) Science 275, 523-527
57. Onate, S. A., Tsai, S. Y., Tsai, M.-J., and O'Malley, B. W. (1995) Science 270, 1354-1357
58. Vogel, J. J., Heine, M. J. S., Zechel, C., Chambon, P., and Gronemeyer, H. (1996) EMBO J. 15, 101-108
59. Na, S.-Y., Lee, S.-K., Han, S.-J., Choi, H.-S., Im, S.-Y., and Lee, J. W. (1998) J. Biol. Chem. 273, 10831-10834
60. LeDouarin, B., Nielsen, A. L., Garnier, J. M., Ichinose, H., Jeanmougin, F., Losson, R., and Chambon, P. (1996) EMBO J. 15, 6701-6715
61. Heery, D. M., Kalkhoven, K., Hoare, S., and Parker, M. G. (1997) Nature 387, 733-736
62. Torchia, J., Rose, D. W., Inostroza, J., Kamei, Y., Westin, S., Glass, C. K., and Rosenfeld, M. G. (1997) Nature 387, 677-684
63. Schmitz, M. L., Stelzer, G., Altmann, H., Meisterernst, M., and Baeuerle, P. A. (1995) J. Biol. Chem. 270, 7219-7226
64. Heck, S., Bender, K., Kullmann, M., Gsttlicher, M., Herrlich, P., and Cato, A. C. B. (1997) EMBO J. 16, 4689-4707
65. Aarnisalo, P., Santti, H., Poukka, H., Palvimo, J. J., and Jänne, O. A. (1999) Endocrinology 140, 3097-3105
66. Heck, S., Kullmann, M., Gast, A., Ponta, H., Rahmsdorf, H. J., Herrlich, P., and Cato, A. C. B. (1994) EMBO J. 13, 4087-4095
67. Reichardt, H. M., Kaestner, K. H., Tuckermann, J., Kretz, O., Wessely, O., Bock, R., Gass, P., Schmid, W., Herrlich, P., Angel, P., and Schütz, G. (1998) Cell 93, 531-541
68. Cerillo, G., Rees, A., Manchanda, N., Reilly, C., Brogan, I., White, A., and Needham, M. (1998) J. Steroid Biochem. Mol. Biol. 67, 79-88
69. Saatcioglu, F., Lopez, G., West, B. L., Zandi, E., Feng, W., Lu, H., Esmaili, A., Apriletti, J. W., Kushner, P. J., Baxter, J. D., and Karin, M. (1997) Mol. Cell. Biol. 17, 4687-4695
70. Merika, M., Williams, A. J., Chen, G., Collins, T., and Thanos, D. (1998) Mol. Cell 1, 277-287
71. Wissink, S., van Heerde, E. C., van der Burg, B., and van der Saag, P. T. (1998) Mol. Endocrinol. 12, 355-363
72. De Bosscher, K., Schmitz, M. L., Vanden Berghe, W., Plaisance, S., Fiers, W., and Haegeman, G. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 13504-13509
73. Brostjan, C., Anrather, J., Csizmadia, V., Stroka, D., Soares, M., Bach, F. H., and Winkler, H. (1996) J. Biol. Chem. 271, 19612-19616
74. Iafrati, M. D., Karas, R. H., Aronovitz, M., Kim, S., Sullivan, T. R., Lubahn, D. B., O'Donnell, T. F., Korach, K. S., and Mendelsohn, M. E. (1997) Nat. Med. 3, 545-548

Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.